TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30858609

Group type: EXPERIMENTAL
Intervention: 4400 IU vitamin D daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: 400 IU vitamin D daily (Control)
Number of subjects: 0
Study: 29774628

Group type: EXPERIMENTAL
Intervention: brexpiprazole 2 mg
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: brexpiprazole 4 mg
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: brexpiprazole 1 mg
Number of subjects: 459

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 459
Study: 26836351

Group type: EXPERIMENTAL
Intervention: Handtevy LBT™
Number of subjects: 80

Group type: COMPARATOR
Intervention: Broselow Pediatric Emergency Tape™
Number of subjects: 80
Study: 24457632

Group type: EXPERIMENTAL
Intervention: 3-drug therapy (N = 14)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 5-drug therapy (N = 26)
Number of subjects: 40
Study: 22992714

Group type: EXPERIMENTAL
Intervention: Education (for men)
Number of subjects: 1789

Group type: EXPERIMENTAL
Intervention: Education (for women)
Number of subjects: 1789

Group type: EXPERIMENTAL
Intervention: Being married (for men)
Number of subjects: 1789

Group type: EXPERIMENTAL
Intervention: Being married (for women)
Number of subjects: 1789
Study: 20595280

Group type: EXPERIMENTAL
Intervention: Internet-based self-management program with telephone support
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (weekly attention-control phone calls)
Number of subjects: 46
Study: 18056185

Group type: EXPERIMENTAL
Intervention: Complete remission (CR) in patients with multiple myeloma
Number of subjects: 326
Study: 11491010

Group type: EXPERIMENTAL
Intervention: albendazole 400 mg with ivermectin 200 micrograms/kg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: albendazole 400 mg with diethylcarbamazine citrate (DEC) 6 mg/kg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: albendazole 600 mg with ivermectin 400 micrograms/kg
Number of subjects: 47
Study: 9122358

Group type: EXPERIMENTAL
Intervention: 50 mg oral naltrexone
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 8319375

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3520133

Group type: COMPARATOR
Intervention: 20 mg BAYo1248 administered prior to breakfast
Number of subjects: 0

Group type: COMPARATOR
Intervention: 50 mg BAYm1099 administered prior to breakfast, lunch, and dinner
Number of subjects: 0

Group type: COMPARATOR
Intervention: BAYo1248 and BAYm1099
Number of subjects: 0
Study: 30504569

Group type: EXPERIMENTAL
Intervention: Gabapentin (2400 mg/d, tid) + pulsed radiofrequency lesioning of the dorsal root ganglion
Number of subjects: 116

Group type: COMPARATOR
Intervention: Oral gabapentin (2400 mg/d, tid)
Number of subjects: 116
Study: 27240921

Group type: EXPERIMENTAL
Intervention: Oral L-tryptophan (30, 60 or 120 mg/kg body weight)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 25630245

Group type: EXPERIMENTAL
Intervention: Antagonist passive static stretching (AS) for 40 seconds applied to pectoralis major prior to each set of seated row (SR)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Antagonist passive static stretching (AS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Passive recovery (PR)
Number of subjects: 10
Study: 23895804

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 2600

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent with biolinx polymer (ZES-R)
Number of subjects: 2600

Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stent (BES)
Number of subjects: 2600
Study: 20619837

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fenofibrate (160 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of atorvastatin and fenofibrate
Number of subjects: 0
Study: 18199184

Group type: EXPERIMENTAL
Intervention: Solution-focused group therapy (SFGT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional problem-focused treatment
Number of subjects: 0
Study: 16523206

Group type: EXPERIMENTAL
Intervention: EFA‐supplemented test‐treatment formula
Number of subjects: 53

Group type: COMPARATOR
Intervention: Fat-free control formula
Number of subjects: 53
Study: 12895320

Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg daily
Number of subjects: 429
Study: 10983204

Group type: EXPERIMENTAL
Intervention: 4-tiered hospital-approved disciplinary action
Number of subjects: 1638
Study: 8646820

Group type: EXPERIMENTAL
Intervention: Oral administration of midazolam (2 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravenous administration of midazolam (1 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: In vitro studies of CYP3A-mediated formation of 1'‐hydroxymidazolam
Number of subjects: 20
Study: 1345890

Group type: EXPERIMENTAL
Intervention: BRL 26830A
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31871697

Group type: EXPERIMENTAL
Intervention: Educational brochures and films about diabetes prevention (N=154)
Number of subjects: 311

Group type: COMPARATOR
Intervention: No intervention (N=157)
Number of subjects: 311
Study: 29266804

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 26094771

Group type: EXPERIMENTAL
Intervention: Supragingival scaling
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: RA group
Number of subjects: 52
Study: 24902406

Group type: EXPERIMENTAL
Intervention: ACTIVA BioACTIVE‐CEMENT/BASE/LINER
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: FujiCem2
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Embrace WetBond
Number of subjects: 40

Group type: COMPARATOR
Intervention: zinc phosphate cement
Number of subjects: 40
Study: 22434523

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (daily calcium 1 g and vitamin D(3) 800 IU, plus additional oral 16,000 IU every 2 weeks if baseline 25(OH)D <30 ng/ml)
Number of subjects: 232
Study: 21245499

Group type: EXPERIMENTAL
Intervention: CT extension
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CT flexion
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CC extension
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CC flexion
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Extensor to flexor strength ratio at CT axis
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Extensor to flexor strength ratio at CC axis
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Test-retest repeatability (all tests)
Number of subjects: 40
Study: 17852958

Group type: EXPERIMENTAL
Intervention: Health-promotion programme
Number of subjects: 229

Group type: COMPARATOR
Intervention: Individual intervention
Number of subjects: 229
Study: 19305697

Group type: EXPERIMENTAL
Intervention: Income-based pharmacare policy change in 2003
Number of subjects: 795071

Group type: EXPERIMENTAL
Intervention: Co-payment introduced in 2002
Number of subjects: 795071
Study: 14612828

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 180
Study: 11115795

Group type: COMPARATOR
Intervention: N-acetylcysteine
Number of subjects: 0
Study: 8668568

Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen (N2O)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oxygen (O2)
Number of subjects: 20
Study: 1460158

Group type: EXPERIMENTAL
Intervention: Integrated systemic therapy (IST)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotionally focused therapy (EFT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 6425033

Group type: EXPERIMENTAL
Intervention: One nitroglycerin plaster (5 mg liberation within 24 hours)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Two nitroglycerin plasters (5 mg liberation within 24 hours)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Four nitroglycerin plasters (5 mg liberation within 24 hours)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 20 mg 5‐isosorbide mononitrate (ISMN)
Number of subjects: 24
Study: 31586443

Group type: EXPERIMENTAL
Intervention: Mobilization tool
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparator tool
Number of subjects: 60
Study: 29887537

Group type: EXPERIMENTAL
Intervention: Higher dietary cholesterol intake (1 SD increase) in nonemployed men
Number of subjects: 1039

Group type: EXPERIMENTAL
Intervention: Higher dietary cholesterol intake (1 SD increase) in less educated men
Number of subjects: 1039

Group type: EXPERIMENTAL
Intervention: Higher dietary cholesterol intake (1 SD increase) in employed men
Number of subjects: 1039

Group type: EXPERIMENTAL
Intervention: Higher dietary cholesterol intake (1 SD increase) in more educated men
Number of subjects: 1039
Study: 29140826

Group type: EXPERIMENTAL
Intervention: Robot-assisted walking training with rhythmic arm swing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group performing training in arm fixation
Number of subjects: 20
Study: 27941179

Group type: EXPERIMENTAL
Intervention: Flaxseed oil supplementation for three months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Safflower oil treatment for three months
Number of subjects: 0
Study: 24561815

Group type: EXPERIMENTAL
Intervention: COLD (cold water bath at 10°C for 15 min)
Number of subjects: 9

Group type: COMPARATOR
Intervention: CON (control leg outside the water bath)
Number of subjects: 9
Study: 22585532

Group type: EXPERIMENTAL
Intervention: FT laparoscopic operation
Number of subjects: 163

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 163
Study: 21166343

Group type: EXPERIMENTAL
Intervention: Fluoxetine hydrochloride for 3 months
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (stroke patients without depression)
Number of subjects: 85
Study: 18308580

Group type: EXPERIMENTAL
Intervention: Adenosine (250 microg/kg) added to blood cardioplegia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (only antegrade cardioplegia)
Number of subjects: 40
Study: 16041209

Group type: EXPERIMENTAL
Intervention: Antimicrobial-impregnated catheters (minocycline and rifampin)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Tunneled catheters
Number of subjects: 346
Study: 12503837

Group type: EXPERIMENTAL
Intervention: Olanzapine (5 mg/day titrated to 20 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10424419

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) over primary motor cortex (MI)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) over FCz
Number of subjects: 7
Study: 7472629

Group type: EXPERIMENTAL
Intervention: Nurse managed special care unit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional intensive care units
Number of subjects: 0
Study: 2265045

Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 micrograms kg‐1 5 min before induction of anaesthesia
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no fentanyl)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg kg‐1
Number of subjects: 17
Study: 6777109

Group type: EXPERIMENTAL
Intervention: Heavy exercise (70% maximum power)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Light exercise (36% maximum power)
Number of subjects: 5
Study: 31709903

Group type: EXPERIMENTAL
Intervention: Prevention of Post‐Rape Stress (PPRS) video intervention
Number of subjects: 233

Group type: COMPARATOR
Intervention: Pleasant Imagery and Relaxation Instruction (PIRI) video intervention
Number of subjects: 233

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 233
Study: 31574862

Group type: EXPERIMENTAL
Intervention: Fixed AFO
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Articulated AFO
Number of subjects: 50
Study: 28209343

Group type: EXPERIMENTAL
Intervention: Intradermal vaccination
Number of subjects: 347

Group type: COMPARATOR
Intervention: Intramuscular vaccination
Number of subjects: 347
Study: 25458756

Group type: EXPERIMENTAL
Intervention: Family-centred tobacco control programme
Number of subjects: 26
Study: 24006861

Group type: EXPERIMENTAL
Intervention: Topical ocular hypotensive medication for 12 weeks
Number of subjects: 164
Study: 21236411

Group type: EXPERIMENTAL
Intervention: Deep anterior lamellar keratoplasty (DALK)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Penetrating keratoplasty (PK)
Number of subjects: 53
Study: 19764167

Group type: EXPERIMENTAL
Intervention: Transposition at two months post-fitting (V4)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Transposition at initial fit (V2)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Transposition at one month post-fit (V3)
Number of subjects: 8
Study: 18193499

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention (15 sessions, 90 minutes each) focusing on Stress, Coping, and Adjustment; Safer Behaviors; and Health Behaviors, including ART adherence.
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (no intervention until trial completion).
Number of subjects: 204
Study: 12027908

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (untreated subjects)
Number of subjects: 23
Study: 9607529

Group type: EXPERIMENTAL
Intervention: Intravenous cephazolin 1 g every 6 h and gentamicin 80 mg every 8 h for 7 days
Number of subjects: 127

Group type: COMPARATOR
Intervention: No antibiotics until the appearance of infective complications
Number of subjects: 127
Study: 7530585

Group type: EXPERIMENTAL
Intervention: Nevirapine 200 mg/day in combination with zidovudine 200 mg q8h
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Nevirapine at doses of 12.5, 50, and 200 mg/day
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Nevirapine alone or in combination with zidovudine
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 62
Study: 2223677

Group type: EXPERIMENTAL
Intervention: Prophylactic oral salbutamol (74 women)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo (70 women)
Number of subjects: 144
Study: 395632

Group type: EXPERIMENTAL
Intervention: Phthalylsulphathiazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Faeces
Number of subjects: 0
Study: 30889600

Group type: EXPERIMENTAL
Intervention: Learning to read the non-extension sign through a 60-minute lecture.
Number of subjects: 35
Study: 31221206

Group type: EXPERIMENTAL
Intervention: Prophylactic placement of Phasix™ mesh in an onlay position
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standardized abdominal closure without mesh
Number of subjects: 0
Study: 27839752

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine‐impregnated antiseptic washcloths
Number of subjects: 122

Group type: COMPARATOR
Intervention: Nonantiseptic bathing
Number of subjects: 122
Study: 25844702

Group type: EXPERIMENTAL
Intervention: Experimental system for bedside EDPS process guidance
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no experimental system)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Experimental group (with experimental system)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 23829508

Group type: EXPERIMENTAL
Intervention: HM30181 at doses ≥10 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Loperamide (16 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: HM30181 (1, 5, 10, 15 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: HM30181
Number of subjects: 25
Study: 22364054

Group type: EXPERIMENTAL
Intervention: Doppler method for measuring systolic blood pressure (SBP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Stethoscope method for measuring systolic blood pressure (SBP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of Doppler and Stethoscope methods for determining ABI
Number of subjects: 20

Group type: COMPARATOR
Intervention: Linear regression analysis of Doppler and Stethoscope methods for ABI
Number of subjects: 20
Study: 19583934

Group type: EXPERIMENTAL
Intervention: Needling at SJ5
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Needling at SJ5 plus GB34
Number of subjects: 16
Study: 16735965

Group type: EXPERIMENTAL
Intervention: Reinforced follow-up group (RFG)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual follow-up group (UFG)
Number of subjects: 100
Study: 15655271

Group type: EXPERIMENTAL
Intervention: Continuous simvastatin 10 mg/day for four months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intermittent simvastatin 20 mg three times a week for four months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (diet only)
Number of subjects: 40
Study: 10754624

Group type: EXPERIMENTAL
Intervention: Fentanyl concentration of 0.72 +/- 0.07 ng/ml
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fentanyl concentration of 0.94 +/- 0.06 ng/ml
Number of subjects: 25
Study: 8607590

Group type: EXPERIMENTAL
Intervention: Low-protein diet
Number of subjects: 1521

Group type: COMPARATOR
Intervention: Usual-protein diet
Number of subjects: 1521
Study: 1845927

Group type: EXPERIMENTAL
Intervention: Cholangiocarcinoma in patients with primary sclerosing cholangitis
Number of subjects: 30

Group type: COMPARATOR
Intervention: Medical therapy for primary sclerosing cholangitis
Number of subjects: 30
Study: 6683540

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pentazocine
Number of subjects: 0
Study: 30022574

Group type: EXPERIMENTAL
Intervention: Patient Information Leaflet (PIL)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Drug Monograph
Number of subjects: 96
Study: 28475268

Group type: EXPERIMENTAL
Intervention: Regimen A (standard treatment)
Number of subjects: 874

Group type: COMPARATOR
Intervention: Regimen B (additional doxorubicin and cyclophosphamide/cytarabine)
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Generic HRQoL
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Age and gender effects
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Number of delayed intensifications (DIs)
Number of subjects: 874
Study: 27281811

Group type: EXPERIMENTAL
Intervention: PRO+EX (40 g protein with evening physical activity)
Number of subjects: 23

Group type: COMPARATOR
Intervention: PRO (40 g protein without evening physical activity)
Number of subjects: 23
Study: 25783650

Group type: EXPERIMENTAL
Intervention: Salpingectomy
Number of subjects: 160

Group type: COMPARATOR
Intervention: Aspiration
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Salpingectomy (vs. rapid re-accumulation subgroup)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Rapid re-accumulation subgroup
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Salpingectomy (vs. no re-accumulation subgroup)
Number of subjects: 160

Group type: COMPARATOR
Intervention: No re-accumulation subgroup
Number of subjects: 160
Study: 22550052

Group type: EXPERIMENTAL
Intervention: Total cholesterol
Number of subjects: 2743

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 2743

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 2743

Group type: EXPERIMENTAL
Intervention: Sex and age
Number of subjects: 2743
Study: 20122945

Group type: EXPERIMENTAL
Intervention: Multisensory illusion using fake hands smaller or larger than the participant's hand
Number of subjects: 0
Study: 18602522

Group type: EXPERIMENTAL
Intervention: Diastolic HF
Number of subjects: 228
Study: 15783351

Group type: EXPERIMENTAL
Intervention: Multiscale entropy (MSE) method applied to human heartbeat fluctuations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiscale entropy (MSE) method applied to coding and noncoding DNA sequences
Number of subjects: 0
Study: 12401759

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion
Number of subjects: 79

Group type: COMPARATOR
Intervention: Insulin injection
Number of subjects: 79
Study: 10330958

Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atgam
Number of subjects: 0
Study: 8792953

Group type: EXPERIMENTAL
Intervention: Dornase alfa
Number of subjects: 0
Study: 2189429

Group type: EXPERIMENTAL
Intervention: Oral physostigmine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 16793

Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 0
Study: 31996267

Group type: EXPERIMENTAL
Intervention: Ojeok-san plus Saengmaek-san (5.76 g, three times per day for 6 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (three times per day for 6 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ojeok-san plus Saengmaek-san
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31437539

Group type: EXPERIMENTAL
Intervention: Multi-disciplinary integrated care (gastroenterologist, gut-hypnotherapist, psychiatrist, behavioral therapist, dietician)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (gastroenterologist or colorectal surgeon)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-disciplinary integrated care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 28105731

Group type: EXPERIMENTAL
Intervention: liraglutide (1.8 mg/d)
Number of subjects: 32
Study: 25770176

Group type: EXPERIMENTAL
Intervention: Oral ergocalciferol, 50,000 IU weekly (n=36)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Oral ergocalciferol, 50,000 IU monthly (n=33)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo (n=36)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Oral ergocalciferol, 50,000 IU weekly
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Oral ergocalciferol, 50,000 IU monthly
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Ergocalciferol-treated participants
Number of subjects: 105
Study: 23209111

Group type: EXPERIMENTAL
Intervention: Specialized breastfeeding peer counseling (SBFPC)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Standard care (controls)
Number of subjects: 206
Study: 21596046

Group type: EXPERIMENTAL
Intervention: Oxytocin infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0